Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,517 | 487 | 2,983 |
| Samples | 541 | 109 | 423 |
| Peptides | 481 | 82 | 396 |
Function
NRP1 · Neuropilin 1
This gene encodes one of two neuropilins, which contain specific protein domains which allow them to participate in several different types of signaling pathways that control cell migration. Neuropilins contain a large N-terminal extracellular domain, made up of complement-binding, coagulation factor V/VIII, and meprin domains. These proteins also contains a short membrane-spanning domain and a small cytoplasmic domain. Neuropilins bind many ligands and various types of co-receptors; they affect cell survival, migration, and attraction. Some of the ligands and co-receptors bound by neuropilins are vascular endothelial growth factor (VEGF) and semaphorin family members. This protein has also been determined to act as a co-receptor for SARS-CoV-2 (which causes COVID-19) to infect host cells. [provided by RefSeq, Nov 2020].
Isoforms & Proteins
9 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000374867 | O14786 | 540 | 386 |
| ENST00000265371 | O14786 | 481 | 367 |
| ENST00000395995 | E9PEP6* | 472 | 359 |
| ENST00000374875 | Q5JWQ6* | 368 | 292 |
| ENST00000374816 | E7EX60* | 351 | 253 |
| ENST00000374823 | Q5T7F0* | 350 | 263 |
| ENST00000374822 | O14786-2 | 340 | 255 |
| ENST00000374821 | O14786-3 | 326 | 243 |
| ENST00000432372 | Q5JWQ4* | 289 | 218 |
Gene Properties
Recurrent Mutations
All 386 amino-acid changes on canonical ENST00000374867 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NRP1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NRP1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 7/133 5% |
| Unknown | 0/10 0% | 2/29 7% |
| Endometrial Carcinoma | 1/42 2% | 28/612 5% |
| Melanoma | 12/210 6% | 77/1899 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Colorectal Carcinoma | 17/143 12% | 60/3239 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Cervical Carcinoma | 0/35 0% | 10/422 2% |
| Burkitts Lymphoma | 5/32 16% | 0/196 0% |
| Squamous Cell Lung Carcinoma | 8/57 14% | 11/810 1% |
| Bladder Carcinoma | 2/58 3% | 13/956 1% |
| Gastric Carcinoma | 3/74 4% | 23/1809 1% |
| Other Solid Cancers | 4/94 4% | 18/1515 1% |
| Neuroendocrine Tumour | 6/154 4% | 4/577 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 15/1390 1% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Non-Cancerous | 2/104 2% | 7/830 1% |
| Osteosarcoma | 1/45 2% | 1/166 1% |
| Ewings Sarcoma | 1/63 2% | 2/262 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 14/1592 1% |
| Head and Neck Carcinoma | 2/85 2% | 11/1574 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 18/2550 1% |
| Breast Carcinoma | 5/144 3% | 21/3264 1% |
| Glioma | 0/52 0% | 16/2127 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Biliary Tract Carcinoma | 0/54 0% | 7/950 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 3/752 0% |
Mutation Distribution
Where NRP1 is mutated · all tissues, split by cell line vs tissue
How many mutations in NRP1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,517 mutations in NRP1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|